e23221 Background: The emergence of bispecific antibodies as off-the-shelf immunotherapy for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and multiple myeloma (MM) has important implications for community oncologists. Guidance on implementation remains incomplete despite efforts to outline integration strategies (Crombie J et al. Blood. 2024;143:1565-157; Garfall A et al. Front Oncol. 2025;15:1630146). Assessing clinician preparedness to use bispecific antibodies can inform interventions supporting safe adoption of T-cell–engaging (TCE) immunotherapy amid evolving guidelines and regulatory approvals. To assess preparedness among community clinicians, educational programs were delivered between May 2024 and January 2026 focused on bispecific antibodies in DLBCL, FL, and MM. Methods: Interventions included 10 Project ECHO sessions, 15 meetings within US Oncology Network practices, and 3 live programs at medical congresses, with associated enduring activities. Data were analyzed through qualitative evaluation of expert-facilitated peer-to-peer dialogues to identify adoption behaviors, operational strategies, and implementation barriers. Quantitative learner assessments contextualized qualitative findings. In total, 3,059 learners participated, including hematologist-oncologists, nurse practitioners, physician associates, and oncology nurses. Results: Before intervention, most clinicians reported no or limited experience with bispecific antibodies. Proficiency in integrating bispecifics was low at baseline (37% of respondents; N = 1,524), particularly for decision-making during step-up dosing, but increased to 71% post-intervention (N = 1,215; p < 0.05). Qualitative analyses (N = 396) showed growing interest in outpatient delivery, dosing de-escalation to mitigate toxicity, and greater involvement of interprofessional team members. Clinicians also reported willingness to adopt co-management models with academic colleagues. Key challenges included complex step-up dosing logistics, limited outpatient monitoring readiness, and constrained access to supportive care resources. Conclusions: Community oncology clinicians are increasingly incorporating bispecific antibodies into routine care for patients with DLBCL, FL, and MM but continue to face logistical and skill-based implementation barriers. Community-based interventions can identify challenges limiting real-world adoption and improve clinician preparedness through interprofessional education. These findings highlight the need for education addressing operational workflows, team-based care, and real-world clinical decision-making to support broader implementation of bispecific therapies in community settings.
Deluca et al. (Thu,) studied this question.